GlaxoSmithKline and ChemoCentryx announce initiation of Phase III study of GSK’786, formerly Traficet-EN™, for the treatment of Crohn’s disease
GSK & ChemoCentryx announced, first patient with Crohn's disease has initiated treatment in study comparing Traficet-EN, to placebo.
Read the full article15y agoen
You might also wanna read
OpenAI No. 2 Executive Fidji Simo Steps Down from Full-Time Role to Focus on Health Recovery
Variety·4h ago
Why ambulance rides in the US are so expensive: The broken economics of emergency medical transport
davidoks.blog·6h agoModerna's mResvia gets shot in the arm from EU contract
pharmaphorum·6h ago
Australia news live: Hanson defends UK ‘fact-finding’ trip; Qantas tops airline punctuality table
The Guardian·6h ago
STAT+: FDA finalists under review
STAT·13h ago
STAT+: Prime wins Beam arbitration, clearing path to clinic
STAT·14h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.